Directors' Dealings

RNS Number : 2900B

hVIVO plc

09 January 2018

 

For immediate release 7.00am: 9 January 2018

HVIVO PLC

("hVIVO" or the "Company")

 

Directors' Dealings

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that application has been made to AIM for the admission of 23,675 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jaime Ellertson (Non-Executive Chairman) and Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of their letters of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Ellertson and Mr Winschel had entered into binding commitments to purchase $20,000 and £4,000 of hVIVO plc new ordinary shares respectively per quarter.  On 7 June 2017 Jaime Ellertson volunteered to reduce his Director's fee by 10% to $180k pa, then on 13 November 2017 his role changed from Non-Executive Chairman to Non-Executive Director and his Director's fee reduced to £50k pa.  His quarterly purchase of shares has reduced accordingly as 40% of his Director's fee.

The New Ordinary Shares represent their investments for the quarter ended 31 December 2017.  On 8 January 2018, Mr Ellertson invested in an additional 16,401 ordinary shares and Mr Winschel invested in an additional 7,274 ordinary shares, at a price of 55.0 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 78,197,542 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 11 January 2018.  Following Admission, Mr Ellertson and Mr Winschel will be interested in a total of 128,814 and 57,397 ordinary shares of 5.0p in the Company respectively, representing 0.2% and less than 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the persons discharging managerial responsibilities/persons closely associated
a)	Name	Jaime Ellertson and Jim Winschel
2	Reason for the notification
a)	Position/ status	Non-Executive Director
b)	Initial notification/ Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 5 pence each  GB00B6ZM0X53
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Currency	GBP
d)	Price(s) and volume(s)	Director Price (p) Volume Jaime Ellertson 55.0 16,401 Jim Winschel 55.0 7,274
e)	Aggregated information - Aggregated volume - Price - Aggregated total	23,675 55.0p £13,021.25
f)	Date of the transaction	8 January 2018
g)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

hVIVO plc	[phone]
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries	[phone]
Susan Flood (Head of Marketing)
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)	[phone]
John Capodanno / Evan Smith (US)	[phone]

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 

END

 

 

DSHUGUQAGUPRPPR